APS is produced by further centrifuging and dehydrating PRP to extract high concentrations of proteins that help suppress inflammation and growth factors that protect cartilage. Also known as “next-generation PRP,” it is expected to be more effective than standard PRP in reducing joint pain and inflammation, as well as in inhibiting cartilage degeneration and destruction.
This treatment involves injecting APS—derived from the patient’s own blood—into the affected area (target condition: osteoarthritis of the knee). APS is produced using a medical device approved by the Ministry of Health, Labour and Welfare as a medical device whose safety for therapeutic use has been confirmed. Generally, tissue repair begins within about 1 to 4 weeks, and effects are expected to be seen within 2 weeks to 3 months after treatment. Additionally, treatment reports from overseas indicate that a single injection of APS can provide lasting benefits for up to approximately 24 months.
*All treatments are completed on the same day.
お問い合わせ